Myriad Genetics (MYGN) vs Neogen (NEOG)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Neogen (NEOG) has outperformed Myriad Genetics (MYGN) over the past year, gaining 74.8% versus a loss of 45.0%. Over five years, NEOG leads with a -71.1% price change compared with -86.8% for MYGN. Neogen is the larger company by market cap ($2.59 billion vs $412.2 million), about 6.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MYGN | NEOG |
|---|---|---|
| Share price | $4.31 | $11.85 |
| Market cap | $412.25M | $2.59B |
| 1-day change | +2.62% | +1.20% |
| YTD return | -31.71% | +69.53% |
| 1-year return | -45.03% | +74.78% |
| 5-year return | -86.77% | -71.13% |
| Forward P/E | — | 31.18 |
| EPS (TTM) | $-1.18 | $-0.26 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $870.40M |
| Revenue growth (YoY) | — | -2.72% |
| Net income (latest FY) | — | $-7.90M |
| Gross margin | — | 46.93% |
| Operating margin | — | -2.48% |
| Net margin | — | -0.91% |
| 52-week high | $8.59 | $14.26 |
| 52-week low | $2.74 | $5.37 |
| Distance from 52-week high | -49.83% | -16.90% |
| Analyst consensus | hold | buy |
| Avg. price target upside | -9.28% | +18.14% |
| Average volume | 2.04M | 3.14M |
| Shares outstanding | 95.65M | 218.31M |
| Employees | 2,700 | 2,636 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Neogen is about 6.3 times larger than Myriad Genetics by market value ($2.59B vs $412.25M).
- NEOG has outperformed MYGN by 119.8 percentage points over the past year.
About Myriad Genetics
MYGN stock →Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 2,700 employees
About Neogen
NEOG stock →Neogen Corporation develops, manufactures, and markets various products and services for food and animal safety in the United States and internationally. It operates through Food Safety and Animal Safety segments.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 2,636 employees
MYGN vs NEOG FAQ
Which is bigger, Myriad Genetics or Neogen?
Neogen (NEOG) is larger, with a market capitalization of $2.59B compared with $412.25M for Myriad Genetics (MYGN).
Which stock has performed better over the past year, MYGN or NEOG?
NEOG returned +74.78% over the past 12 months, compared with -45.03% for MYGN (price return, excluding dividends). Past performance does not predict future results.
Are Myriad Genetics and Neogen in the same industry?
Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.